Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786512 · ClinicalTrials.gov registry record · Phase 2
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 544
- Enrollment target
NCT01786512 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 544 participants.
The verdict
NCT01786512, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 544 participants
- Enrollment target
Study Summary
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Omecamtiv Mecarbil Matrix F1 Formulation
- DRUG Omecamtiv Mecarbil Matrix F2 Formulation
- DRUG Omecamtiv Mecarbil Swellable Core Technology F2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2013-02-26 |
| Est. Completion | 2015-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786512
The ClinicalTrials.gov registry entry for NCT01786512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 544 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01786512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786512 about?
NCT01786512 is a clinical study titled "COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure". The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks...
What is the current status of trial NCT01786512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 544 participants. The study started on 2013-02-26. Estimated completion is 2015-08-19.
What interventions are being tested in trial NCT01786512?
The interventions under investigation include: Placebo (DRUG), Omecamtiv Mecarbil Matrix F1 Formulation (DRUG), Omecamtiv Mecarbil Matrix F2 Formulation (DRUG), Omecamtiv Mecarbil Swellable Core Technology F2 (DRUG).
Who is sponsoring clinical trial NCT01786512?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.